EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology

Omonigho Michael Bubu iD, Anna E Mullins, Shreshtha Shah, Joshua L Gills, Korey Kam, Ankit Parekh, Ogie Q Umasabor-Bubu, Arlener D Turner, Mark Bernard, Anthony Briggs, Jaime Ramos-Cejudo, Elena Valkanova and 14 more

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71270 ↗

At a glance

Journal article in Alzheimer's & Dementia, 2026. Written by Omonigho Michael Bubu and 25 co-authors. Institution: Healthy Brain Aging and Sleep Center, Department of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA. Major MEDLINE topics: Sleep Apnea, Obstructive, Alzheimer Disease, Amyloidosis, Patient Acuity. Cited 1 times so far (Crossref); 70 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIH HHS, NIA NIH HHS, Alzheimer's Association/Michael J. Fox Foundation/CurePSP.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

INTRODUCTION We examined obstructive sleep apnea (OSA) severity's association with Alzheimer's disease (AD) plasma biomarkers, independent or synergistic with cerebrospinal fluid (CSF) amyloid, and as a proof of concept, whether plasma amyloid beta (Aβ)42/Aβ40 with OSA severity improves detection of amyloidosis and tau pathology. METHODS In 120 cognitively normal older adults (70 with CSF data) from New York University sleep and aging studies (2013–2021), OSA severity was measured using apnea/hypopnea index with 4% desaturation; plasma Aβ40, Aβ42, tau, and neurofilament light chain (NfL) via single molecule array; CSF amyloid and tau via enzyme‐linked immunosorbent assay. Associations evaluated adjusted correlations and generalized models; receiver operating characteristic analyses evaluated diagnostic accuracy. RESULTS OSA severity correlated with plasma Aβ40 ( r = 0.21), Aβ42 ( r = 0.26), and Aβ42/Aβ40 ( r = 0.20). Plasma tau and NfL associations depended on CSF–Aβ42. OSA severity with Aβ42/Aβ40 improved CSF amyloidosis (area under the curve [AUC] = 0.78) and tau pathology (AUC = 0.71) detection. DISCUSSION OSA severity relates to elevated plasma Aβ and, with CSF amyloid, to tau/NfL. Combined plasma and OSA measures aid non‐invasive AD associations’ detection.

Subjects

MeSH terms (MEDLINE)

Sleep Apnea, ObstructiveAlzheimer DiseaseAmyloidosisPatient AcuityHumansBiomarkerstau ProteinsAmyloid beta-PeptidesNeurofilament ProteinsMaleFemaleMiddle AgedAgedPeptide Fragments

Author keywords

Alzheimer's diseaseamyloidobstructive sleep apneaplasma biomarkers

Substances

Biomarkerstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)neurofilament protein LNeurofilament ProteinsPeptide Fragments

Authors and institutions

  • Healthy Brain Aging and Sleep Center, Department of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA.
  • Institute of Excellence in Health Equity, Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA.
  • Alzheimer's Disease Research Center and Center for Cognitive Neurology, Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
  • Neuroscience Institute, New York University Grossman School of Medicine, New York, New York, USA.
  • Division of Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Epidemiology and Infection Control, State University of New York Downstate Medical Center, Brooklyn, New York, USA.

ORCID profiles: Omonigho Michael Bubu

Funding

  • NIH HHS
  • NIA NIH HHS
  • Alzheimer's Association/Michael J. Fox Foundation/CurePSP
  • BrightFocus Foundation
  • Alzheimer's Association
  • National Institutes of Health

Cite

APA

Bubu, O. M., Mullins, A. E., Shah, S., Gills, J. L., Kam, K., Parekh, A., Umasabor-Bubu, O. Q., Turner, A. D., Bernard, M., Briggs, A., Ramos-Cejudo, J., Valkanova, E., Mbah, A. K., Pahari, P., Debure, L., Ghuman, M., Boutajangout, A., Williams, N. J., Hwang, J., …, & Osorio, R. S. (2026). Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71270

Vancouver

Bubu OM, Mullins AE, Shah S, Gills JL, Kam K, Parekh A, et al. Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71270

BibTeX
@article{Bubu2026,
  author = {Bubu, Omonigho Michael and Mullins, Anna E and Shah, Shreshtha and Gills, Joshua L and Kam, Korey and Parekh, Ankit and Umasabor-Bubu, Ogie Q and Turner, Arlener D and Bernard, Mark and Briggs, Anthony and Ramos-Cejudo, Jaime and Valkanova, Elena and Mbah, Alfred K and Pahari, Purbanka and Debure, Ludovic and Ghuman, Mobeena and Boutajangout, Allal and Williams, Natasha J and Hwang, Jeongyeon and Williams, Masrai K and Rapoport, David M and Ayappa, Indu and de Léon, Mony and Jean-Louis, Girardin and Varga, Andrew W and Osorio, Ricardo S},
  title = {Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71270}
}
Start for free →